<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646499</url>
  </required_header>
  <id_info>
    <org_study_id>131887a</org_study_id>
    <secondary_id>R21AG060335</secondary_id>
    <nct_id>NCT04646499</nct_id>
  </id_info>
  <brief_title>Feasibility of Gamma Transcranial Alternating Current Stimulation to Reduce Beta-amyloid Load and Improve Memory</brief_title>
  <official_title>Feasibility of Gamma Transcranial Alternating Current Stimulation to Reduce Beta-amyloid Load and Improve Memory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will assess the feasibility of transcranial alternating current stimulation in&#xD;
      the gamma band to lower beta-amyloid load and improve memory performance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Side effects</measure>
    <time_frame>post-tACS (after one day of treatment)</time_frame>
    <description>12 side effects will be measured on a scale from 0 (not noticable) to 10 (not tolerable): headache, neck pain, scalp pain, tingling, itching, burning sensation, increased sleepiness, trouble concentrating, acute mood change, phosphenes, back pain, dizziness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drop out</measure>
    <time_frame>post-tACS (after one month of treatment)</time_frame>
    <description>Drop out rate will be assessed as the number of participants who withdraw or are withdrawn from the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta amyloid load</measure>
    <time_frame>pre-tACS (baseline), post-tACS (after one month of treatment)</time_frame>
    <description>Change in plasma beta amyloid load will be assessed pre and post intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory: Recall</measure>
    <time_frame>pre-tACS (baseline), post-tACS (after one month of treatment)</time_frame>
    <description>Change in episodic memory will be assessed pre and post intervention as accuracy for word lists from the California Verbal Learning Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory: Paired Associates</measure>
    <time_frame>pre-tACS (baseline), post-tACS (after one month of treatment)</time_frame>
    <description>Change in episodic memory will be assessed pre and post intervention from memory accuracy for a paired associates task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory: Fluency</measure>
    <time_frame>pre-tACS (baseline), post-tACS (after one month of treatment)</time_frame>
    <description>Change in episodic memory will be assessed pre and post intervention from performance on the FAS task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tau</measure>
    <time_frame>pre-tACS (baseline), post-tACS (after one month of treatment)</time_frame>
    <description>Change in plasma tau levels will be assessed pre and post intervention.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Resting state functional connectivity (RSFC)</measure>
    <time_frame>pre-tACS</time_frame>
    <description>RSFC will be assessed as a predictor of tACS effects. Modularity will be calculated and used in a regression model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Resting state functional connectivity (RSFC)</measure>
    <time_frame>pre-tACS (baseline), post-tACS (after one month of treatment)</time_frame>
    <description>Change in RSFC will be assessed pre and post intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Magnetic resonance spectroscopy (MRS)</measure>
    <time_frame>pre-tACS</time_frame>
    <description>MRS will be assessed as a predictor of tACS effects. The ratio of excitatory (GLX+) to inhibitory (GABA) neurotransmitters will be used in a regression model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Magnetic resonance spectroscopy (MRS)</measure>
    <time_frame>pre-tACS (baseline), post-tACS (after one month of treatment)</time_frame>
    <description>Change in MRS will be assessed pre and post intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Modeled electric field (EF)</measure>
    <time_frame>pre-tACS</time_frame>
    <description>EF will be assessed as a predictor of tACS effects. EF magnitude will be calculated from T1 and T2 images, and used in a regression model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Instrumental activities of daily living (IADL)</measure>
    <time_frame>pre-tACS (baseline), post-tACS (after one month of treatment)</time_frame>
    <description>Change in IADL will be assessed pre and post intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurofilament Light</measure>
    <time_frame>pre-tACS (baseline), post-tACS (after one month of treatment)</time_frame>
    <description>Change in blood neurofilament light levels will be assessed pre and post intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurogranin</measure>
    <time_frame>pre-tACS (baseline), post-tACS (after one month of treatment)</time_frame>
    <description>Change in blood neurogranin levels will be assessed pre and post intervention.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Gamma Stimulation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive gamma stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial alternating current stimulation</intervention_name>
    <description>Transcranial alternating current stimulation (tACS) will be applied at 40 Hz (gamma band) during eight sessions over the course of a month.</description>
    <arm_group_label>Gamma Stimulation Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Grade 12 or more education&#xD;
&#xD;
          -  Normal or corrected to normal vision and hearing&#xD;
&#xD;
          -  Ability to complete cognitive tasks&#xD;
&#xD;
          -  Ability to cooperate and comply with all study procedures&#xD;
&#xD;
          -  Ability to tolerate tACS&#xD;
&#xD;
          -  Self-reported memory complaint&#xD;
&#xD;
          -  Diagnosed with mild cognitive impairment&#xD;
&#xD;
          -  Amyloid positive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neurological or psychiatric disorders other than mild cognitive impairment&#xD;
&#xD;
          -  Receiving investigational medications or have participated in a trial with&#xD;
             investigational medications within last 30 days&#xD;
&#xD;
          -  Family history of epilepsy&#xD;
&#xD;
          -  Implanted electronic devices (e.g., pacemaker)&#xD;
&#xD;
          -  Prior head trauma&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  IQ &lt; 80&#xD;
&#xD;
          -  Taking cholinesterase inhibitory, memantine, or psychotropic medication&#xD;
&#xD;
          -  Taking anti-depressants or anti-anxiety medication&#xD;
&#xD;
          -  Color blind&#xD;
&#xD;
          -  Substance abuse&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Macular degeneration&#xD;
&#xD;
          -  Amblyopia (lazy eye)&#xD;
&#xD;
          -  Strabismus (crossed eyes)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodore Zanto, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theodore Zanto, Ph.D.</last_name>
    <phone>415-364-8209</phone>
    <email>theodore.zanto@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Avery Ostrand, B.S.</last_name>
    <phone>415-364-8209</phone>
    <email>avery.ostrand@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avery Ostrand, B.S.</last_name>
      <phone>415-364-8209</phone>
      <email>avery.ostrand@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized IPD will be shared in accordance with NIH guidelines and IRB approval.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

